tadalafil and ambrisentan upfront combination therapy
ApprovedCompleted 1 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Pulmonary Arterial Hypertension
Conditions
Pulmonary Arterial Hypertension, Systemic Sclerosis, Scleroderma Spectrum of Diseases, Connective Tissue Disease, Pulmonary Hypertension
Trial Timeline
Jan 1, 2010 → Nov 1, 2014
NCT ID
NCT01042158About tadalafil and ambrisentan upfront combination therapy
tadalafil and ambrisentan upfront combination therapy is a approved stage product being developed by Eli Lilly for Pulmonary Arterial Hypertension. The current trial status is completed. This product is registered under clinical trial identifier NCT01042158. Target conditions include Pulmonary Arterial Hypertension, Systemic Sclerosis, Scleroderma Spectrum of Diseases.
What happened to similar drugs?
20 of 20 similar drugs in Pulmonary Arterial Hypertension were approved
Approved (20) Terminated (1) Active (0)
✅Arformoterol Tartrate Inhalation Solution + Arformoterol Tartrate Inhalation Solution + PlaceboSumitomo PharmaApproved
✅Arformoterol Tartrate Inhalation Solution + Tiotropium + Arformoterol and Tiotropium + PlaceboSumitomo PharmaApproved
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01042158 | Approved | Completed |
Competing Products
20 competing products in Pulmonary Arterial Hypertension